ARX.AX Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: October 18, 2025
Report Source: 2025 Annual Report
Aroa Biosurgery Ltd. Stock Analysis ARX.AX
Aroa Biosurgery Ltd. engages in the development, manufacturing, and marketing of soft tissue repair products. The company develops, manufactures, sells, and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from the AROA extracellular matrix (ECM) technology platform, an extracellular matrix biomaterial derived from the ovine forestomach. AROA ECM is an ECM biomaterial containing a rich and complex mix of biological molecules that serve as the building blocks for a range of soft tissue repair products. Its products include Endoform, Myriad Matrix, Myriad Morcells, Myriad Morcells Fine, Symphony, and Reinforced Bioscaffolds. Endoform products support all phases of wound healing and are appropriate for use early in wound management to restore protease balance and advance healing to the proliferative phase. Myriad Matrix is an engineered ECM designed for soft tissue repair, reinforcement, and complex wounds.
Read More Aroa Biosurgery Ltd (ARX.AX) Chart
Key Statistics of Aroa Biosurgery Ltd (ARX.AX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
AUD0.62Volume
221.67KP/E Ratio (TTM)
-52 Week Range
Market Cap
221.38MAvg. Volume
22.61KDividend Yield
-Financial Metrics & Statements of Aroa Biosurgery Ltd (ARX.AX)
FAQ's for Aroa Biosurgery Ltd (ARX.AX)
- According to Musaffa’s Shariah screening methodology, Aroa Biosurgery Ltd (ARX.AX) is currently classified as HALAL as of October 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.